Table 2.
Changes from baseline in lipid levels and inflammatory parameters during the 52-week treatment period.
| Parameter | All Participants | Baseline eGFR Category | ||||
|---|---|---|---|---|---|---|
| G1 | G2 | G3a–G3b | G4–G5 | |||
| TG (mmol/L) | n | 189 | 21 | 123 | 34 | 8 |
| Baseline | 2.82 (0.88) | 2.94 (1.03) | 2.80 (0.89) | 2.88 (0.86) | 2.72 (0.47) | |
| Week 52 (LOCF) | 1.48 (0.69) | 1.71 (0.87) | 1.47 (0.72) | 1.36 (0.44) | 1.64 (0.54) | |
| % Change | −45.9 (21.8) *** | −41.4 (23.0) *** | −45.8 (23.1) *** | −51.1 (15.4) *** | −37.7 (23.6) ** | |
| HDL-C (mmol/L) | n | 189 | 21 | 123 | 34 | 8 |
| Baseline | 1.18 (0.27) | 1.24 (0.36) | 1.19 (0.24) | 1.19 (0.31) | 0.87 (0.22) | |
| Week 52 (LOCF) | 1.33 (0.34) | 1.29 (0.44) | 1.34 (0.32) | 1.38 (0.35) | 1.18 (0.37) | |
| % Change | 13.1 (17.1) *** | 3.6 (16.9) | 11.9 (16.2) *** | 17.0 (13.0) *** | 34.1 (23.7) ** | |
| TG/HDL-C [(mmol/L)/(mmol/L)] | n | 189 | 21 | 123 | 34 | 8 |
| Baseline | 2.58 (1.22) | 2.69 (1.52) | 2.49 (1.13) | 2.69 (1.37) | 3.30 (0.95) | |
| Week 52 (LOCF) | 1.27 (0.85) | 1.58 (1.03) | 1.24 (0.87) | 1.09 (0.55) | 1.68 (1.12) | |
| % Change | −49.7 (25.7) *** | −40.5 (33.2) *** | −48.9 (26.5) *** | −57.0 (15.9) *** | −51.0 (22.4) *** | |
| LDL-C (mmol/L) | n | 189 | 21 | 123 | 34 | 8 |
| Baseline | 3.09 (0.82) | 3.20 (0.88) | 3.08 (0.78) | 2.96 (0.72) | 3.42 (1.18) | |
| Week 52 (LOCF) | 3.02 (0.75) | 3.12 (0.89) | 3.03 (0.76) | 2.97 (0.62) | 2.82 (0.85) | |
| % Change | 2.2 (30.4) | 2.7 (33.7) | 2.1 (29.2) | 5.1 (30.0) | −8.8 (41.2) | |
| non HDL-C (mmol/L) | n | 189 | 21 | 123 | 34 | 8 |
| Baseline | 4.03 (0.79) | 4.18 (0.87) | 4.00 (0.73) | 3.92 (0.61) | 4.54 (1.34) | |
| Week 52 (LOCF) | 3.63 (0.83) | 3.77 (1.01) | 3.64 (0.85) | 3.56 (0.66) | 3.49 (0.96) | |
| % Change | −8.7 (18.8) *** | −8.3 (21.1) | −8.4 (17.4) *** | −7.7 (18.0) * | −17.3 (33.5) | |
| RemL-C (mmol/L) | n | 187 | 21 | 122 | 34 | 7 |
| Baseline | 0.48 (0.26) | 0.54 (0.30) | 0.46 (0.26) | 0.48 (0.26) | 0.59 (0.15) | |
| Week 52 (LOCF) | 0.18 (0.13) | 0.21 (0.15) | 0.18 (0.14) | 0.17 (0.09) | 0.24 (0.17) | |
| % Change | −57.2 (28.7) *** | −59.9 (21.1) *** | −56.0 (31.8) *** | −59.3 (22.9) *** | −57.1 (25.8) ** | |
| apoA1 (mg/dL) | n | 187 | 21 | 122 | 34 | 7 |
| Baseline | 131.6 (19.8) | 134.2 (22.0) | 132.2 (18.2) | 133.5 (20.0) | 105.4 (19.7) | |
| Week 52 (LOCF) | 137.6 (22.4) | 133.8 (26.0) | 137.2 (20.0) | 144.0 (25.5) | 122.4 (20.8) | |
| % Change | 5.0 (11.2) *** | 0.0 (13.9) | 4.1 (10.5) *** | 8.0 (10.0) *** | 16.7 (10.6) ** | |
| apoA2 (mg/dL) | n | 187 | 21 | 122 | 34 | 7 |
| Baseline | 30.3 (4.5) | 31.4 (5.1) | 30.8 (4.2) | 29.5 (4.7) | 24.2 (3.3) | |
| Week 52 (LOCF) | 38.2 (6.9) | 37.9 (5.9) | 38.7 (6.8) | 37.8 (6.8) | 32.8 (7.1) | |
| % Change | 27.0 (19.5) *** | 22.2 (18.4) *** | 26.3 (17.6) *** | 29.4 (22.7) *** | 35.3 (21.7) ** | |
| apoB (mg/dL) | n | 187 | 21 | 122 | 34 | 7 |
| Baseline | 93.6 (16.8) | 95.6 (17.8) | 93.4 (16.5) | 91.9 (13.8) | 97.4 (23.5) | |
| Week 52 (LOCF) | 88.1 (18.6) | 93.0 (23.1) | 88.0 (18.5) | 87.9 (15.4) | 76.1 (21.6) | |
| % Change | −4.5 (19.9) ** | −1.9 (19.6) | −4.5 (19.6) * | −3.0 (17.7) | −18.1 (29.5) | |
| apoB48 (μg/mL) | n | 188 | 21 | 123 | 34 | 7 |
| Baseline | 9.1 (5.8) | 10.3 (6.7) | 8.5 (5.4) | 9.1 (5.6) | 12.8 (4.1) | |
| Week 52 (LOCF) | 3.8 (3.0) | 3.7 (2.1) | 3.3 (2.8) | 4.0 (2.1) | 7.8 (4.1) | |
| % Change | −53.0 (30.9) *** | −60.4 (21.5) *** | −54.4 (33.0) *** | −48.1 (26.6) *** | −34.9 (34.4) * | |
| apoC3 (mg/dL) | n | 187 | 21 | 122 | 34 | 7 |
| Baseline | 15.1 (4.5) | 15.9 (5.0) | 14.7 (4.3) | 15.9 (5.2) | 13.2 (1.1) | |
| Week 52 (LOCF) | 9.8 (3.2) | 10.6 (3.8) | 9.3 (3.1) | 10.5 (2.5) | 10.5 (2.9) | |
| % Change | −32.4 (19.6) *** | −32.4 (15.3) *** | −34.2 (20.1) *** | −30.0 (18.3) *** | −20.2 (22.6) | |
| hsCRP (mg/dL) | n | 186 | 21 | 123 | 33 | 6 |
| Baseline | 0.11 (0.20) | 0.18 (0.43) | 0.09 (0.11) | 0.13 (0.19) | 0.23 (0.39) | |
| Week 52 (LOCF) | 0.13 (0.26) | 0.23 (0.58) | 0.12 (0.19) | 0.13 (0.15) | 0.06 (0.03) | |
| Change | 0.02 (0.30) | 0.04 (0.71) | 0.03 (0.17) | −0.00 (0.22) | −0.17 (0.37) | |
| IL-1β (pg/mL) | n | 183 | 21 | 123 | 31 | 5 |
| Baseline | 0.16 (0.22) | 0.21 (0.28) | 0.15 (0.20) | 0.17 (0.28) | 0.13 (0.10) | |
| Week 52 (LOCF) | 0.09 (0.08) | 0.08 (0.08) | 0.08 (0.08) | 0.11 (0.10) | 0.13 (0.12) | |
| Change | −0.07 (0.24) *** | −0.13 (0.31) * | −0.06 (0.22) *** | −0.06 (0.30) | −0.00 (0.17) | |
Data are presented as means (SD). Baseline eGFR categories are as follows: G1, eGFR ≥ 90 mL/min/1.73 m2; G2, eGFR ≥ 60 and <90 mL/min/1.73 m2; G3a–G3b, eGFR ≥ 30 and <60 mL/min/1.73 m2; G4–G5, eGFR < 30 mL/min/1.73 m2. Three patients in hemodialysis were included in the all participants category but were excluded from the G4–G5 category. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. baseline by Wilcoxon signed-rank tests for hsCRP and IL-1β, and by one sample t-tests for all others. LOCF, last-observation-carried-forward; eGFR, estimated glomerular filtration rate; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; RemL-C, remnant lipoprotein cholesterol; Apo, apolipoprotein; hsCRP, high-sensitivity C-reactive protein; IL-1β, interleukin 1β; SD, standard deviation.